CODX vs. PYPD, POCI, NMTC, DRIO, COCH, OSRH, TMDIF, QTI, FEMY, and XAIR
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include PolyPid (PYPD), Precision Optics (POCI), NeuroOne Medical Technologies (NMTC), DarioHealth (DRIO), Envoy Medical (COCH), OSR (OSRH), Titan Medical (TMDIF), QT Imaging (QTI), Femasys (FEMY), and Beyond Air (XAIR). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs. Its Competitors
Co-Diagnostics (NASDAQ:CODX) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.
PolyPid has a net margin of 0.00% compared to Co-Diagnostics' net margin of -1,025.45%. Co-Diagnostics' return on equity of -60.16% beat PolyPid's return on equity.
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 8.4% of Co-Diagnostics shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Co-Diagnostics currently has a consensus target price of $5.50, indicating a potential upside of 1,823.08%. PolyPid has a consensus target price of $11.80, indicating a potential upside of 238.11%. Given Co-Diagnostics' higher probable upside, equities research analysts clearly believe Co-Diagnostics is more favorable than PolyPid.
PolyPid has lower revenue, but higher earnings than Co-Diagnostics. PolyPid is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Co-Diagnostics and Co-Diagnostics both had 1 articles in the media. Co-Diagnostics' average media sentiment score of 0.93 equaled PolyPid'saverage media sentiment score.
Co-Diagnostics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.
Summary
PolyPid beats Co-Diagnostics on 7 of the 13 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 7/3/2025 by MarketBeat.com Staff
